First-in-class antibody medicines grounded in human biology

Bluefin Biomedicine is a privately held, clinical-stage biotechnology company advancing first-in-class antibody medicines anchored in human biology. Our integrated discovery platform combines proteomics-powered antigen identification with next-generation antibody engineering to resolve target expression within complex human tissues.

This human tissue-anchored approach reveals previously inaccessible biology across immune pathways and tumor intrinsic or tumor-associated mechanisms. Guided by these insights, we advance a focused portfolio of differentiated biologics designed to address serious inflammatory and oncologic diseases where current therapies fall short.